Mitiglinide

DB01252InvestigationalSmall molecule

Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

Mechanism: Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.
Curator reviewed
Primary indication: For the treatment of type 2 diabetes.Curator reviewed · 2 structured indications
Formula / weight: C₁₉H₂₅NO₃ · 315.413 g/mol (avg)

Resolves to

Compound

UNIID86I0XLB13CAS145375-43-5ChEMBLCHEMBL471498ChEBI135349PubChem121891KEGGD01854

Clinical / RWD

ATCA10BX08PharmGKBPA164748124

Structure

InChIKeyWPGGHFDDFPHPOB-BBWFWOEESA-NSMILES[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O

Targets

Q09428ABCC8P78508KCNJ10P37231PPARG

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

621Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

4Marketed productsAcross 1 country and 3 labellers

1ATC codeIncluding every combination product, plus 7 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mitiglinide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In